Understanding the Shareholder Concerns Around CARGO Therapeutics, Inc.’s Transaction with Concentra Biosciences
Background to the Shareholder Investigation An investigation has been launched to assess if CARGO Therapeutics, Inc. (NASDAQ: CRGX ) is securing a fair price for its public shareholders amid its transaction with Concentra Biosciences . This probe centers on whether the terms of the deal uphold the fiduciary duties owed to shareholders or if potential breaches and other legal violations are at play. Details of the Transaction Offer In this deal, CARGO shareholders are slated to receive $4.379 in cash per share , accompanied by a non-transferable contingent value right (CVR). The CVR is structured to grant two specific benefits: 100% of the closing net cash surplus of CARGO exceeding $217.5
